Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?

To: WTT2 who wrote (672)	8/24/1998 9:29:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 1722

Centocor Inc. (CNTO): The biotechnology company was reiterated ''strong buy'' by analyst Caroline Copithorne at Prudential Securities Inc., who predicts the stock will reach 70 in 12 months. The company's ReoPro drug showed benefits over a six-month period in heart patients fitted with common artery- clearing devices called stents, follow-up data showed, confirming 30-day results presented earlier. Even though approval for this indication isn't expected until late 1999 or early 2000, the study's expected to give ReoPro a distinct advantage, Copithorne said. Centocor rose 3/8 to 37 3/4. From Bloomberg News August 24, 1998, 5:59 a.m. PT